Red carpeting the newer antidiabetics

Journal of Pharmacology and Pharmacotherapeutics

Volumn 3, Issue 2, 2012, Pages 127-131

  Gude, Dilip ^a  

^a Medwin Hospital   (India)

Author keywords

Glucokinase activators; newer antidiabetics; Sodium glucose transport proteins 2 inhibitors

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOKINASE ACTIVATOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; MONOCLONAL ANTIBODY; NEW DRUG; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; REMOGLIFLOZIN; SAXAGLIPTIN; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

BLADDER CANCER; BREAST CANCER; DIABETES MELLITUS; DIABETOGENESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIVER TOXICITY; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; REVIEW;

EID: 84878793212     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.95507     Document Type: Review

References (54)

1. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43
2. Sabino-Silva R, Mori RC, David-Silva A, Okamoto MM, Freitas HS, Machado UF. The Na(+)/glucose cotransporters: From genes to therapy. Braz J Med Biol Res 2010;43:1019-26
3. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
4. FDA Briefing Document. NDA 202293. Dapagliflozin Tablets, 5 and 10mg. Sponsor: Bristol-Myers Squibb. Advisory Committee Meeting, July 19, 2011. Available from: Http://www.fda.gov/downloads/Advisory Committees/ CommitteesMeetingMaterials/Drugs/Endocrinologic and Metabolic Drugs Advisory Committee/UCM262994.pdf [Last accessed on 2011 Oct 17].
5. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-Affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008;327:268-76
6. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609:148-54
7. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents? Regul Pept 2005;128:159-65
8. Hausenloy DJ, Wynne AM, Theodorou L, Mocanu MM, Yellon DM. FC1 Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose-sensitive manner. Heart 2010;96:e11
9. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
10. Sahelian R. Sitagliptin Phosphate a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Available from: Http://www.raysahelian.com/ sitagliptin.html [Last accessed on 2011 Sep 08].
11. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, et al. Fifty-Two-week efficacy and safety of vildagliptin vs.glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66
12. Kulasa K, Edelman S. Saxagliptin: The evidence for itsplace in the treatment of type 2 diabetes mellitus. Core Evid 2010;5:23-37
13. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86
14. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers-cell function in patients with inadequately controlled type 2 diabetes: A?of randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
15. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem 2009;24:1061-6
16. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: A disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011;34:369-74
17. Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: Interactions with metformin. Diabetes 2009;58:1604-15
18. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 2011;6:e25269
19. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
20. Best JH, Rubin RR, Peyrot M, Li Y, Yan P, Malloy J, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care 2011;34:314-9
21. Christensen M, Knop FK, Vilsbøll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 2011;20:549-57
22. Sanofi. "Lyxumia® (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes". Press release. Retrieved 2011-09-13. Available from: Http://en.sanofi.com/press/ - medias/20110912-EASD-Lyxumia-en.pdf [Last accessed on 2011 Sep 12].
23. Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: A 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab 2011;13:81-8
24. Goldenberg MM. Pharmaceutical Approval Update. P T 2010;35:216-8
25. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-Albumin protein (albugon) mimicspeptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53:2492-500
26. Matschinsky FM, Zelent B, Doliba NM, Kaestner KH, Vanderkooi JM, Grimsby J, et al. Research and development of glucokinase activators for diabetes therapy: Theoretical and practical aspects. Handb Exp Pharmacol 2011;203:357-401
27. Sebokova E, Christ AD, Wang H, Sewing S, Dong JZ, Taylor J, et al. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. Endocrinology 2010;151:2474-82
28. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowersplasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: A mechanistic study. J Clin Endocrinol Metab 2010;95:5028-36
29. Evaluate Pharma. Zydus' IND Application of ZYGK1 for Treating Diabetes Receives USFDA Approval. Press release. Retrieved 2011-09-13. Available from: Http://www.evaluatepharma.com/Universal/View. aspx?type=Storyandid=244462 [Last accessed on 2011 July 04].
30. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferatoractivated receptors (ppar) co-Agonism: The bezafibrate lessons. Cardiovasc Diabetol 2005;4:14
31. Hansen BC, Tigno XT, Bénardeau A, Meyer M, Sebokova E, Mizrahi J. Effects of aleglitazar, a balanced dual peroxisome agonist on glycemic and lipid parameters in proliferator-Activated receptor a primate model of the metabolic syndrome. Cardiovasc Diabetol 2011;10:7
32. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-Activated receptor-Alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study. Lancet 2009;374:126
33. Dzyakanchuk A, Wright MB, Sebokova, E, Wabitsch M, Fischer-Posovszky P, Keuper M, et al. Abstract 10854: Aleglitazar, a balanced dual ppar alpha/ gamma agonist, decreases lipolysis and cytokine production in a cellular model of inflamed human adipose tissue. Circulation 2010;122:A10854
34. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6
35. Miller SA, St Onge E. Otelixizumab: A novel agent for the prevention of type 1 diabetes mellitus. Expert Opin Biol Ther 2011;11:1525-32
36. Masharani UB, Becker J. Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther 2010;10:459-65
37. Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, et al. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-cd20monoclonal antibody (Rituximab) therapy in type 1 diabetes. J Immunol 2011;187:1998-2005
38. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010;5:1420-8
39. Owyang AM, Maedler K, Gross L, Yin J, Esposito L, Shu L, et al. XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology 2010;151:2515-27
40. Keche Y. Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control. J Pharm Bioallied Sci 2010;2:148-50
41. Cefalu WT, Rood J, Pinsonat P, Qin J, Sereda O, Levitan L, et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism 2010;59:755-62
42. Jain SK, Croad JL, Velusamy T, Rains JL, Bull R. Chromium dinicocysteinate supplementation can lower blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFkappaB, Akt, and Glut-2 in livers of zucker diabetic fatty rats. Mol Nutr Food Res 2010;54:1371-80
43. Fernández-Alvarez J, Barberà A, Nadal B, Barceló-Batllori S, Piquer S, Claret M, et al. Stable and functional regeneration of pancreatic beta-cell population in nSTZ-rats treated with tungstate. Diabetologia 2004;47:470-7
44. Altirriba J, Barbera A, Del Zotto H, Nadal B, Piquer S, Sánchez-Pla A, et al. Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach. BMC Genomics 2009;10:406
45. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C. Vanadium treatment of type 2 diabetes: A view to the future. J Inorg Biochem 2009;103:554-8
46. Smith DM, Pickering RM, Lewith GT. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitis. QJM 2008;101:351-8
47. Henry MB, Zheng S, Duan C, Patel B, Vassileva G, Sondey C, et al. Antidiabetic properties of the histamine H3 receptor protean agonist proxyfan. Endocrinology 2011;152:828-35
48. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, et al. Antidiabetic actions of a non-agonist pparligand blocking Cdk5- mediated phosphorylation. Nature 2011;477:477-81
49. Aumeunier A, Grela F, Ramadan A, Pham Van L, Bardel E, Gomez Alcala A, et al. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One 2010;5:e11484
50. Sobel DO, Henzke A, Abbassi V. Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetol 2010;47:243-50
51. He K, Chan CB, Liu X, Jia Y, Luo HR, France SA, et al. Identification of a molecular activator for insulin receptor with potent anti-diabetic effects. J Biol Chem 2011 Sep 9. [Epub ahead of print]
52. Gupta R, Sharma AK, Dobhal MP, Sharma MC, Gupta RS.-sitosterol in?Antidiabetic and antioxidant potential of streptozotocin-induced experimental hyperglycemia. J Diabetes 2011;3:29-37
53. Saravanan G, Ponmurugan P, Senthil Kumar GP, Rajarajan T. Antidiabetic effect of S-Allylcysteine: Effect on plasma and tissue glycoproteins in experimental diabetes. Phytomedicine 2010;17:1086-9
54. El-Azab MF, Attia FM, El-Mowafy AM. Novel role of curcumin combined with bone marrow transplantation in reversing experimental diabetes: Effects on pancreatic islet regeneration, oxidative stress, and inflammatory cytokines. Eur J Pharmacol 2011;658:41-8